ArticleMolecular and cellular pediatrics2015
Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies.
Article in Molecular and cellular pediatrics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potentialMolecular therapy. Nucleic acids · 2023Article
- RNA ImmunoGenic Assay: A Method to Detect Immunogenicity ofBio-protocol · 2020Article
- Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments.Pharmaceutics · 2020Article
- The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages.Journal of innate immunity · 2020Article
- Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Gene correction of HBB mutations in CD34Molecular and cellular pediatrics · 2018Article
- Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis.Scientific reports · 2018Article
- Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes.Journal of the Endocrine Society · 2017Review
- Synthetic mRNA devices that detect endogenous proteins and distinguish mammalian cells.Nucleic acids research · 2017Article
- Intracellular delivery of messenger RNA by recombinant PP7 virus-like particles carrying low molecular weight protamine.BMC biotechnology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe immunogenicity and limited stability of conventional messenger RNA (mRNA) has traditionally restricted its potential therapeutic use. In 1992, the first clinical application of mRNA was reported as a potential protein-replacement therapy; however, subsequent investigations have not been made for almost two decades. Recent developments, including increased stability, controlling immunogenicity, as well as utilization of mRNA encoding zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9, have implicated modified mRNA as a very promising option for cancer immunotherapy, vaccines, protein expression replacement, and genome editing. This review aims to offer a summary of our present understanding of and improvements in mRNA-based drug technologies, along with a focus on the role in therapeutic options for pediatric respiratory diseases and hemoglobinopathies.
conclusionsThis mini review summarizes the recent advances in modified mRNA-based therapy and its potential therapeutic effect in treating major pediatric diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.